Psilocybe mushrooms, psilocybin & psilocin



Jump to:



Page 4

Koçak. De Cotiis & Hoffman (2010). Comparative study of ATR and transflection IR spectroscopic techniques for the analysis of hallucinogenic mushrooms. Forensic Science International.

Laussmann & Meier-Giebing (2010). Forensic analysis of hallucinogenic mushrooms and khat (Catha edulis Forsk) using cation-exchange liquid chromatography. Forensic Science International.

Manevski et al. (2010). Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases. Drug Metabolism and Disposition.

Wark & Galliher (2010). Timothy Leary, Richard Alpert (Ram Dass) and the changing definition of psilocybin. International Journal of Drug Policy.

Carhart-Harris et al. (2011). The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: A preliminary investigation of tolerability. Journal of Psychopharmacology.

Griffiths et al. (2011). Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology.

Grob et al. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry.

MacLean et al. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology.

Kometer et al. (2011). The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biological Psychiatry.

Shoda et al. (2011). Enzyme-assisted synthesis of the glucuronide conjugate of psilocin, an hallucinogenic component of magic mushrooms. Drug Testing and Analysis.

Studerus et al. (2011). Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. Journal of Psychopharmacology.

van Amsterdam et al. (2011). Harm potential of magic mushroom use: a review.

Carhart-Harris et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. PNAS.

Carhart-Harris et al. (2012). Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. The British Journal of Psychiatry.

Kometer et al. (2012). Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biological Psychiatry.

Johnson, Sewell & Griffiths (2012). Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug and Alcohol Dependence.

Lim, Wasywich & Ruygrok (2012). A fatal case of 'magic mushroom' ingestion in a heart transplant recipient. Internal Medicine Journal.

Lyvers & Meester (2012). Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Journal of Psychoactive Drugs.

MacLean et al. (2012). Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study of Religion.

Martin et al. (2012). A validated method for quantitation of psilocin in plasma by LC-MS/MS and study of stability. International Journal of Legal Medicine.

Quednow et al. (2012). Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology.

Roiser & Rees (2012). Neuroimaging: A Scanner, Colourfully. Current Biology.

Studerus et al. (2012). Prediction of psilocybin response in healthy volunteers. PLoS ONE. 

Bogenschutz (2013). Studying the effects of classic hallucinogens in the treatment of alcoholism: rationale, methodology, and current research with psilocybin. Current Drug Abuse Reviews.

Carhart-Harris (2013). Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophrenia Bulletin.

Catlow et al. (2013). Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Experimental Brain Research.

Cummins & Lyke (2013). Peak experiences of psilocybin users and non-users. Journal of Psychoactive Drugs.

Hallock et al. (2013). A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students. Drug and Alcohol Dependence.

Jastrzebski & Bala (2013). [The impact of psilocybin on visual perception and spatial orientation--neuropsychological approach]. Psychiatria Polska.

Kometer et al. (2013). Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. The Journal of Neuroscience.

Kosentka et al. (2013). Evolution of the toxins muscarine and psilocybin in a family of mushroom-forming fungi. PLOS One.

Krebs & Johansen (2013). Psychedelics and Mental Health: A Population Study. PLoS ONE.

Martin et al. (2013). Determination of psilocin, bufotenine, LSD and its metabolites in serum, plasma and urine by SPE-LC-MS/MS. International Journal of Legal Medicine.

Müller et al. (2013). [Suicide under the influence of "magic mushrooms"]. Archiv fur Kriminologie.

Muthukumaraswamy et al. (2013). Broadband cortical desynchronization underlies the human psychedelic state. The Journal of Neuroscience.

Pellegrini et al. (2013). Magic truffles or Philosopher's stones: a legal way to sell psilocybin? Drug Testing and Analysis.

Schmidt et al. (2013). The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology.

Stebelska (2013). Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities. Therapeutic Drug Monitoring.

Young (2013). Single treatments that have lasting effects: Some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin. Journal of Psychiatry & Neuroscience.

Bernasconi et al. (2014). Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin. Cerebral Cortex.

Bradstreet et al. (2014). Characterization of challenging experiences (i.e., bad trips) after ingesting psilocybin. Drug and Alcohol Dependence.

Carhart-Harris et al. (2014). The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience.

Dos Santos (2014). Potential therapeutic effects of psilocybin/psilocin are minimized while possible adverse reactions are overrated.

Garcia-Romeu, Griffiths & Johnson (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews.

Hendricks (2014). Back to the future: A return to psychedelic treatment models for addiction. Journal of Psychopharmacology.

Hendricks et al. (2014). Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. Journal of Psychopharmacology.

Johnson et al. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology.

Martin et al. (2014). Synthesis, hydrolysis and stability of psilocin glucuronide. Forensic Science International.

Nichols (2014). The Heffter Research Institute: Past and hopeful future. Journal of Psychoactive Drugs.

Rambousek et al. (2014). The effect of psilocin on memory acquisition, retrieval, and consolidation in the rat. Frontiers in Behavioral Neuroscience.

Roseman et al. (2014). The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Frontiers in Human Neuroscience.

Sevanick (2014). Psilocybin-Assisted Psychotherapy in the Treatment of Cancer-Related Psychosocial Distress/Anxiety. Psycho – Oncology.

Tagliazucchi et al. (2014). Enhanced repertoire of brain dynamical states during the psychedelic experience. Human Brain Mapping.